Research programme: metabolic syndrome therapy - BioLineRxAlternative Names: BL-2040
Latest Information Update: 07 May 2007
At a glance
- Originator Weizmann Institute of Science
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 26 Jul 2005 Preclinical trials in Metabolic syndrome in Israel (PO)